These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19130218)

  • 1. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
    Lux MP; Hartmann M; Jackisch C; Raab G; Schneeweiss A; Possinger K; Oyee J; Harbeck N
    Breast Cancer Res Treat; 2009 Sep; 117(2):305-17. PubMed ID: 19130218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
    Ding H; Fang L; Xin W; Tong Y; Zhou Q; Huang P
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28675545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
    Das R; Cope S; Ouwens M; Turner P; Howlett M
    Clin Ther; 2013 Mar; 35(3):246-260.e5. PubMed ID: 23453402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
    Newman MJ; Jones LT; Kraft JM; Lee AR; Lech GM; Farrell NM; Phantumvanit V; Edwards RA
    J Oncol Pharm Pract; 2012 Dec; 18(4):394-401. PubMed ID: 22357638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
    Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
    Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
    Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
    Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
    BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
    Cope S; Ouwens MJ; Jansen JP; Schmid P
    Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
    Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
    Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
    Erman A; Nugent A; Amir E; Coyte PC
    Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.